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Yodthong Baimark* and Yaowalak SrisuwanAbstract
The effects of blend weight ratio and polyester block length of methoxy poly(ethylene glycol)-b-poly(D,L-lactide)
(MPEG-b-PDLL)/methoxy poly(ethylene glycol)-b-poly(E-caprolactone) (MPEG-b-PCL) blends on nanoparticle
characteristics and drug release behaviors were evaluated. The blend nanoparticles were prepared by
nanoprecipitation method for controlled release of a poorly water-soluble model drug, indomethacin. The
drug-loaded nanoparticles were nearly spherical in shape. The particle size and drug loading efficiency slightly
decreased with increasing MPEG-b-PCL blend weight ratio. Two distinct thermal decomposition steps from
thermogravimetric analysis suggested different blend weight ratios. Thermal transition changes from differential
scanning calorimetry revealed miscible blending between MPEG-b-PDLL and MPEG-b-PCL in an amorphous phase.
An in vitro drug release study demonstrated that the drug release behaviors depended upon the PDLL block length
and the blend weight ratios but not on PCL block length.
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Controlled releaseBackground
In the past few decades, biodegradable and biocompat-
ible nanoparticles of methoxy poly(ethylene glycol)-b-
poly(D,L-lactide) (MPEG-b-PDLL) and methoxy poly
(ethylene glycol)-b-poly(E-caprolactone) (MPEG-b-PCL)
amphiphilic diblock copolymers have shown potential as
controlled-release drug delivery carriers because of the
small size of their nanoparticles, which improves circula-
tion time in the body and decreases the administration
frequency when compared to microparticles which are
rapidly cleared by the reticuloendothelial tissue [1,2].
Moreover, for MPEG-b-PDLL and MPEG-b-PCL nano-
particles suspended in water, PDLL and PCL hydropho-
bic cores are surrounded by hydrophilic MPEG blocks
on the nanoparticle surface to solubilize hydrophobic
drugs; this increases blood circulation time and* Correspondence: yodthong.b@msu.ac.th
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reproduction in any medium, provided the origdecreases uptake by the liver of the nanoparticles [3-6].
The need for surfactants when preparing nanoparticles
of amphiphilic diblock copolymer by the nanoprecipita-
tion method can be removed. The protective effect of
the hydrophilic MPEG block is adequate for preventing
nanoparticle aggregation. The poly(vinyl alcohol), Span
series, Tween series, poly(ethylene oxide) (PEO), and
poloxamer (PEO-poly(propylene oxide) block copoly-
mer) have been used as surfactants to stabilize emulsion
droplets [7]. These surfactants remain at the particle sur-
face and are difficult to remove which affect the bio-
degradability and drug release profile of the drug-loaded
particles. Also, these remaining surfactants can influence
the human body, for example, causing an allergy-like
reaction.
In previous studies, much attention was paid to the
drug-loaded nanoparticles of these amphiphilic diblock
copolymers with different types of chemical composi-
tions and lengths of polymer blocks used [8-11]. Drug
release profiles of the nanoparticles depended uponr. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Table 1 Molecular weight characteristics of diblock
copolymers
Diblock copolymer Mn, theoretical (g/mol)
a Mn, GPC (g/mol)
b MWDb
MPEG-b-PDLL30K 35,000 23,000 1.7
MPEG-b-PDLL60K 35,000 49,000 1.8
MPEG-b-PCL30K 65,000 25,000 2.2
MPEG-b-PCL60K 65,000 47,000 1.6
aCalculated based on monomer/MPEG ratio and MPEG molecular weight;
bobtained from gel permeation chromatography (GPC).
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ternative method that has been widely used to adjust the
properties of biodegradable polyesters [12-15]. Thus
unique properties of polymer blends, quite different
from the origin polymers, were obtained. The drug re-
lease rate from poly(L-lactide)/PCL blend nanoparticles
prepared from the nanoprecipitation method using
poloxamer 188 as the surfactant has been adjusted by
varying the blend weight ratios [16].
The characteristics and drug release behaviors of the
MPEG-b-PCL nanoparticles containing drug prepared
by the nanoprecipitation method can be controlled by
adjusting the processing parameters, such as the or-
ganic/water phase volume ratio, polymer concentration,
drug/polymer weight ratio, and stirring speed [17]. How-
ever, the effect of MPEG-b-PDLL/MPEG-b-PCL blend-
ing on characteristics and drug release of the
nanoparticles has not been reported.
In this study, surfactant-free MPEG-b-PDLL/MPEG-b-
PCL blend nanoparticles containing a model drug were
prepared by the nanoprecipitation method. Indometh-
acin was selected as the model drug because of its poor
water solubility. The effects of different polyester block
lengths and blend weight ratios on the nanoparticle
characteristics, drug loading efficiency, and drug release
profiles were studied and discussed.
Methods
Materials
MPEG-b-PDLL and MPEG-b-PCL diblock copolymers
were synthesized by ring-opening polymerization in bulk
under a nitrogen atmosphere as described in the previ-
ous works [18,19]. MPEG with a molecular weight of
5,000 g/mol (Fluka Chemical Corporation, St. Louis,
Milwaukee, WI, USA) and stannous octoate (95%,
Sigma-Aldrich Corporation, St. Louis, MO, USA) were
used as the initiating system. Stannous octoate concen-
tration was kept constant at 0.02 mol%. MPEG-b-PDLL
and MPEG-b-PCL with theoretical PDLL/PCL block
lengths of 30,000 (30 K) and 60,000 (60 K) g/mol were
called MPEG-b-PDLL30K, MPEG-b-PDLL60K, MPEG-
b-PCL30K, and MPEG-b-PCL60K, respectively. The
resulting number-average molecular weights (Mn) and
molecular weight distribution (MWD) of diblock copoly-
mers are summarized in Table 1. Indomethacin model
drug (99%, Sigma-Aldrich Corporation, St. Louis, MO,
USA) was used without further purification. All reagents
used were analytical grade.
Preparation of drug-loaded blend nanoparticles
Drug-loaded blend nanoparticles were prepared via a
nanoprecipitation method. Briefly, 4 mg of indomethacin
and 60 mg of copolymer blend were co-dissolved in 6
mL of acetone. The organic solution was added dropwiseinto 60 mL of distilled water under magnetic stirring.
The nanoparticles were immediately formed after solv-
ent extraction. The organic solvent was then evaporated
at room temperature for 6 h in a fume hood. The drug-
loaded blend nanoparticles with MPEG-b-PDLL/MPEG-
b-PCL blend weight ratios of 100/0, 75/25, 50/50, 25/75,
and 0/100 (w/w) were investigated. The resultant nano-
particle suspensions were centrifuged at 15,000 rpm 4°C
for 2 h. The supernatant was carefully discarded and the
precipitated nanoparticles were then resuspended in a
phosphate buffer solution media (0.1 M, pH 7.4). The
dried drug-loaded nanoparticles were obtained by
freeze-drying the precipitated nanoparticles for 48 h.
Characterization of drug-loaded blend nanoparticles
Morphology of the drug-loaded nanoparticles was deter-
mined by transmission electron microscopy (TEM) using
a JEOL JEM 1230 TEM (JEOL Ltd., Tokyo, Japan). For
TEM analysis, a drop of the nanoparticle suspension was
placed on a formvar film coated on a copper grid. The
specimen on the copper grid was not stained. The aver-
age particle sizes of the drug-loaded nanoparticles were
measured from the nanoparticle suspension by light scat-
tering analysis using a Coulter LS230 particle size
analyzer (Beckman Coulter Inc., Brea, CA, USA) at 25°C.
The thermal decomposition behavior of the dried nano-
particles was characterized by thermogravimetry (TG)
analysis using a TA-Instrument SDT Q600 TG analyzer
(TA Instruments, New Castle, DE, USA). For TG, 5–10
mg of nanoparticles was heated from 50°C to 600°C at
the rate of 20°C/min under a nitrogen atmosphere.
Thermal transition properties of the dried nanoparticles
were determined by mean of non-isothermal differential
scanning calorimetry (DSC) using a Perkin-Elmer Pyris
Diamond DSC (Perkin-Elmer Inc., Waltham, MA, USA).
For DSC, 5–10 mg of nanoparticles was heated at the
rate of 10°C/min under helium flow. The degree of crys-
tallinity of the blend nanoparticles due to PCL
crystallization was calculated according to the following
equation [20],
Crystallinity of blend nanoparticles %ð Þ
¼ ΔHm=135:44½   100 ð1Þ
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and 135.44 J/g is the melting enthalpy for 100% crystal-
line PCL [21].
The theoretical drug loading content (DLCtheoretical),
actual drug loading content (DLCactual), and drug load-
ing efficiency (DLE) were calculated from Equations 2, 3,
and 4, respectively. The DLCactual is an average value
from three measurements. For the DLCactual measure-
ment, the dried drug-loaded nanoparticles were dis-
solved in dichloromethane. The weight of the actual
entrapped drug was then determined by ultraviolet
(UV)–vis spectrophotometry using a Perkin-Elmer
Lambda 25 UV–vis spectrophotometer (Perkin-Elmer
Inc., Waltham, MA, USA) at 319 nm and compared to a
standard curve of indomethacin.
DLCtheoretical %ð Þ ¼ Weight of feed drugWeight of feed drug and copolymer
 100
ð2Þ
DLCactual %ð Þ ¼Weight of actual drug entrapped in nanoparticlesWeight of drug loaded nanoparticles
 100
ð3Þ
DLE %ð Þ ¼ DLCactual
DLCtheoretical
 100 ð4Þ
In vitro drug release
In vitro release of indomethacin from the blend nano-
particles was performed by dialysis bag diffusion tech-
nique. The drug-loaded nanoparticle suspension (10 mL)
was placed in a dialysis bag, tied, and immersed into 100
mL of phosphate buffered saline (0.1 M, pH 7.4). The
entire system was kept at 37°C under shaking at
100 rpm.
At predetermined time intervals, 5 mL aliquots of the
release medium were withdrawn from the release
medium, and the same volume of fresh buffer solution
was added to continue the release test. The concentra-
tion of indomethacin released was monitored using an
UV–vis spectrophotometer at 319 nm. According to a
predetermined indomethacin concentration-UV absorb-
ance standard curve, indomethacin concentration of the
release medium was obtained. Percentage of indometh-
acin release was calculated based on the ratio of drug re-
lease at each release time and initial drug content in the
nanoparticles. The average percentage release was calcu-
lated from the three experiments.Results and discussion
Morphology and size
Morphology of the blend nanoparticles was investigated
by TEM, an example of which is shown in Figure 1 for
the MPEG-b-PDLL30K/MPEG-b-PCL30K blend nano-
particles. It can be seen that they were nearly spherical
in shape for all blend weight ratios. The blend nanopar-
ticles of MPEG-b-PDLL30K/MPEG-b-PCL60K, MPEG-
b-PDLL60K/MPEG-b-PCL30K, and MPEG-b-PDLL60K/
MPEG-b-PCL60K showed similar results. The morph-
ology results suggested that the hydrophilic MPEG
blocks act as the nanoparticle shell to stabilize the nano-
particle formation [18,19]. In these nanoparticles, the
hydrophobic core of the PDLL/PCL blocks is sur-
rounded by the water-soluble polar groups of the MPEG
blocks that extend into the aqueous medium to prevent
nanoparticle aggregation. The polyester block length and
blend weight ratio did not affect the morphology of
drug-loaded blend nanoparticles. The TEM images also
indicate that submicron-sized particles of copolymer
blends can be prepared by the nanoprecipitation method.
The particle size results, from light scattering analysis,
are illustrated in Figure 2. They were less than 140 nm
with a narrow size distribution. The average particle size
slightly decreased as the MPEG-b-PCL blend weight
ratio increased, which may be due to crystallization of
the MPEG-b-PCL component during particle solidifica-
tion that induced nanoparticle shrinkage.
Thermal decomposition
Thermal decomposition of the blend nanoparticles was
determined by TG. The TG thermograms in Figure 3
(top) showed that the thermal resistance of the drug-
loaded nanoparticles of MPEG-b-PCL are better than
MPEG-b-PDLL. The blend nanoparticles, comprised of
two decomposition steps, had maintained distinct ther-
mal stability due to MPEG-b-PDLL decomposition, fol-
lowed by degradation of the MPEG-b-PCL component.
It was found that the TG profiles of the blend nanoparti-
cles strongly depended upon the blend weight ratio. The
amount of weight loss in the first step increased signifi-
cantly when the MPEG-b-PDLL blend weight ratio was
increased, as would be expected, since the blend nano-
particles with various blend weight ratios were success-
fully prepared.
Thermal decomposition can be clearly observed from
differential TG (DTG) thermograms. Figure 3 (bottom)
show DTG thermograms of the MPEG-b-PDLL30K/
MPEG-b-PCL30K blend nanoparticles as examples. The
two-step decomposition process of the blend nanoparti-
cles is clearly illustrated. The peak temperature of the
DTG thermogram is the temperature of maximum de-
composition rate (Td, max). The lower and higher Td, max
values of the DTG thermograms are attributed to
Figure 1 TEM micrographs of drug-loaded nanoparticles with different MPEG-b-PDLL30K/MPEG-b-PCL30K blend weight ratios. All
bars = 50 nm.
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spectively. The Td, max of MPEG-b-PDLL and MPEG-b-
PCL decomposition peaks are in the range of 343°C to
354°C and 400°C to 418°C, respectively, which also indi-
cates higher thermal stability of the MPEG-b-PCL
matrix. It should be noted that the peak areas of the
DTG thermograms strongly depend on the blend weightFigure 2 Average particle sizes of drug-loaded blend
nanoparticles.ratio. It can be clearly seen that the peak area of the
lower temperature peak due to MPEG-b-PDLL decom-
position decreased steadily as the MPEG-b-PDLL blend
weight ratio decreased.
The TG and DTG thermograms of the blend nanopar-
ticles of MPEG-b-PDLL30K/MPEG-b-PCL60K, MPEG-
b-PDLL60K/MPEG-b-PCL30K, and MPEG-b-PDLL60K/
MPEG-b-PCL60K changed with the blend weight ratio
similar to the MPEG-b-PDLL30K/MPEG-b-PCL30K
blend nanoparticles. The thermogravimetry results sup-
ported the fact that MPEG-b-PDLL/MPEG-b-PCL blend
nanoparticles with different blend weight ratios were
obtained.
Thermal transition
The thermal transition of the blend nanoparticles was
studied by DSC. The DSC thermograms of the MPEG-b-
PDLL/MPEG-b-PCL blend nanoparticles are shown as
an example in Figure 4. The melting peak of indometh-
acin is around 165°C and was not observed for all nano-
particles. This may be explained by the indomethacin
molecules being incorporated into the MPEG-b-PDLL
Figure 3 TG (top) and DTG (bottom) thermograms of
drug-loaded nanoparticles with different MPEG-b-PDLL30K/
MPEG-b-PCL30K blend weight ratios.
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methacin crystallizability was then suppressed. Thus the
drug was homogeneously dispersed in an amorphous
form inside the nanoparticle matrix.
The drug-loaded MPEG-b-PDLL nanoparticles were
amorphous (Figure 4a). Meanwhile, the MPEG-b-PCL
and blend nanoparticles exhibited a single melting peak
due to MPEG-b-PCL crystalline (Figures 4b,c,d,e). TheFigure 4 DSC thermograms of drug-loaded nanoparticles with
different MPEG-b-PDLL30K/MPEG-b-PCL30K blend weight
ratios.DSC results, including melting temperature (Tm), melt-
ing enthalpy (ΔHm) and crystallinity of the nanoparticles
are given in Figure 5. The Tm, ΔHm and crystallinity sig-
nificantly decreased with the MPEG-b-PCL blend weight
ratio. This may be explained by the MPEG-b-PCL
crystallization being inhibited by blending with MPEG-
b-PDLL. The results suggest that the MPEG-b-PDLL
and MPEG-b-PCL can be miscible blended in the
amorphous nanoparticle matrix to reduce the Tm, ΔHm
and crystallinity of the MPEG-b-PCL.
Drug loading efficiency
From the feed drug and copolymer blend, the theoretical
drug loading contents (DLCtheoretical) of all blend nano-
particle formulations were calculated from Equation 1,
giving the result of 6.25%. The DLE of the blend nano-
particles were calculated from Equation 3 based on the
DLCtheoretical/actual drug loading content (DLCactual)
ratios that are shown in Figure 6. The DLE was directly
related to the DLCactual. The DLCactual and DLE of
MPEG-b-PDLL nanoparticles were higher than that of
MPEG-b-PCL. The higher chain flexibility of MPEG-b-
PCL is due to its lower glass transition temperature
which induced faster outward drug diffusion duringFigure 5 DSC results. (a) Tm, (b) melting enthalpy, and
(c) crystallinity of drug-loaded blend nanoparticles.
Figure 6 DLE of drug-loaded blend nanoparticles.
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entrapped in the MPEG-b-PCL nanoparticles was less
than the MPEG-b-PDLL nanoparticles. The DLCactual
and DLE of the blend nanoparticles were between
MPEG-b-PDLL and MPEG-b-PCL nanoparticles.
In vitro drug release
The in vitro drug releases from the blend nanoparticles
performed in phosphate buffered saline pH 7.4 at 37°C for
7 days are illustrated in Figure 7. The drug release profilesFigure 7 Drug release profiles from drug-loaded blend nanoparticles.exhibited biphasic features containing a rapid initial burst
release followed by a sustaining release. The rapid initial
burst release of the drug from the blend nanoparticles was
probably due to the releasing of drug that was entrapped
or adsorbed near to the nanoparticle surface. The initial
burst release from the blend nanoparticles was found
within the first 24 h of release time. After that the slow re-
lease may be due to a drug diffusion mechanism.
It can be seen that the drug release contents from
the nanoparticles are in the order MPEG-b-PCL30K
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PDLL60K. The results may be explained due to the crys-
tallinity of the MPEG-b-PCL component which could
lead to formation of a channel structure in the nanopar-
ticle matrix and results in the drug being easily released
from the nanoparticles [10,16]. Zhang et al. [10]
reported that the drug release content from the MPEG-
b-P(CL-co-DLL) nanoparticles increased with the CL
content. For the blend nanoparticles, with increasing
MPEG-b-PCL blend weight ratio, the drug release
increased. The higher crystallinity of the blend nanopar-
ticles is due to the larger MPEG-b-PCL blend weight
ratio, inducing faster drug release from the nanoparti-
cles. The drug release results indicate that the polyester
block type and blend weight ratio were important factors
for controlling the drug release content from the blend
nanoparticles.
Conclusions
In the present study, drug-loaded MPEG-b-PDLL/
MPEG-b-PCL blend nanoparticles with various polyester
block lengths and blend weight ratios were prepared by
nanoprecipitation method. They were nearly spherical in
shape. The average particle size slightly decreased as the
MPEG-b-PCL blend weight ratio increased. The thermal
decomposition behaviors confirm the difference in
MPEG-b-PDLL/MPEG-b-PCL blend weight ratios of the
blend nanoparticles. Melting temperature and melting
enthalpy depression of MPEG-b-PCL indicate the misci-
bility between MPEG-b-PDLL and MPEG-b-PCL com-
ponents in the drug-loaded blend nanoparticle matrix.
The nanoparticles of MPEG-b-PDLL and MPEG-b-
PCL showed the slowest and fastest drug releases, re-
spectively. The drug release behaviors of the blend nano-
particles were between the MPEG-b-PCL and MPEG-b-
PDLL nanoparticles. The drug release from the blend
nanoparticles can be tailored by adjusting the PCL block
length and blend weight ratio. These blend nanoparticles
without any surfactants added are considered to be
promising biodegradable drug carriers for sustained re-
lease of poorly water-soluble drugs.
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